TNF Inhibition as Treatment for Treatment-Resistant Depression

Time: 4:55 pm
day: Day Two


• The role of neuroinflammation in treatment resistant depression: review of the evidence
• Development of a Phase 2 study of the soluble TNF inhibitor Xpro1595 in treatment resistant depression
• Use of noninvasive biomarkers for patient selection, target engagement and treatment response